US FDA approves Basilea Pharmaceutica's antibiotic
April 3 (Reuters) - The U.S. health regulator approved
Basilea Pharmaceutica BSLN.S antibiotic for bacterial
infections including multidrug-resistant strains, the FDA said
on Wednesday.
(Reporting by Sriparna Roy and Unnamalai L in Bengaluru;
Editing by Vijay Kishore)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Basilea Pharmaceutica AG, Allschwil
See all newsBrief: Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment
Basilea seen up after raising 2026 guidance
Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Brief: Basilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At IDWeek 2026
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments